Latest news with #CombinedShareholdersMeeting
Yahoo
17-06-2025
- Business
- Yahoo
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
All resolutions recommended by the Board of Directors approved (quorum: 27.21%). Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 17, 2025. The quorum on first convening amounted to 27.21% and shareholders approved all of the resolutions, with the exception of resolution n°28 which was rejected in accordance with the recommendations of the Board of Directors. The voting results, resolution by resolution, are available in the Investors & Media section of the Company's website (Shareholders Meeting | GENFIT). ABOUT GENFIT GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development: VS-01, G1090N, SRT-015, CLM-022 and VS-02-HE, based on complementary mechanisms of action using different routes of administration. Other assets target other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorder (UCD) and organic acidemia (OA). GENFIT's expertise in the development of high-potential molecules from early to advanced stages, and in pre-commercialization, was demonstrated in the accelerated approval of Iqirvo® (elafibranor1) by the U.S. Food and Drug Administration, the European Medicines Agency and the Medicines and Healthcare Regulatory Agency in the UK for Primary Biliary Cholangitis (PBC). Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis) and TS-01 focusing on blood ammonia levels. GENFIT is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Nasdaq Global Select Market and on the Euronext regulated market in Paris, Compartment B (Nasdaq and Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. FORWARD LOOKING STATEMENTS This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, such as "believe", "potential", "expect", 'target', 'may', 'will', "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company's management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2024 Universal Registration Document filed on April 29, 2025 (no. 25-0331) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website ( and the AMF's website ( and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's 2024 Annual Report on Form 20-F filed with the SEC on April 29, 2025 and subsequent filings and reports filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. CONTACT GENFIT | InvestorsTel: +33 3 2016 4000 | investors@ PRESS RELATIONS | MediaStephanie Boyer – Press relations | Tel: +333 2016 4000 | GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | 1 Elafibranor is marketed and commercialized in the U.S by Ipsen under the trademark Iqirvo®. Attachment GENFIT June 17, 2025 Combined Shareholders Meeting ResultsError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
21-05-2025
- Business
- Business Wire
Combined Shareholders' Meeting of SEB S.A., May 20, 2024
ECULLY, France--(BUSINESS WIRE)--Regulatory News: The Combined Shareholders Meeting of SEB S.A. (Paris:SK) took place on May 20, 2025, and was chaired by Thierry de La Tour d'Artaise, Chairman of the Board of Directors, at 28 Avenue George V in Paris. Shareholders representing 88.24% of voting rights in the Ordinary Annual General Meeting (OAGM) and 88.12% of voting rights in the Extraordinary Annual General Meeting (EAGM), i.e., 4,348 shareholders present or represented by proxy in OAGM and 4,353 shareholders present or represented by proxy in EAGM, adopted all of the resolutions. As Chairman of the Board of Directors, Thierry de La Tour d'Artaise chaired this shareholders' meeting, accompanied by Stanislas de Gramont, Chief Executive Officer, Olivier Casanova, Senior Executive Vice-president, Finance, and Philippe Sumeire, General Secretary, Secretary of the Board of Directors. The General Meeting included presentations on the Group's financial performance in 2024, key highlights of the past year, and the first quarter results of 2025. The Chairman and the CEO then emphasized the pillars underlying the Group's strategy, based on solid fundamentals ensuring growth and resilience in a constantly evolving global environment. The new ESG ambition by 2030 was also introduced. Philippe Sumeire subsequently addressed governance, with the Chairman reviewing the work completed in 2024 by the Board of Directors and its Committees. The presentation concluded with an explanation of the information prior to voting on the resolutions, followed by a discussion session with shareholders. The Shareholders' Meeting approved all of the resolutions presented by the Board, including: The distribution of a dividend of €2.80 1 for the fiscal year 2024. The coupon will be detached on June 3, and the dividend will be paid from June 5, 2025; The renewal of the mandate of Mrs. Brigitte Forestier and the appointment of Mr. Eric Rondolat as Director; Approval of the 2024 remuneration components and the 2025 remuneration policy for all corporate officers. Lastly, on the recommendation of the Governance and Remuneration Committee, the Board of Directors, which met at the end of the Shareholders' Meeting, appointed Mr. Eric Rondolat as a member of the Audit and Compliance Committee, and the Strategic and CSR Committee. The composition of the committees is now as follows: Audit and Compliance Committee: Catherine Pourre (Chair), François Mirallié, Adeline Lemaire, Eric Rondolat; Governance and Remuneration Committee: Jean-Pierre Duprieu (Chair), Damarys Braida, Caroline Chevalley, Brigitte Forestier, Catherine Pourre; Strategic and CSR Committee: Thierry de La Tour d'Artaise (Chair), William Gairard, Adeline Lemaire, Thierry Lescure, Catherine Pourre, Eric Rondolat. The replay of the Shareholders' Meeting is available at: The results of the votes will be made available over the coming days on that same section of the website. Next key dates – 2025 You can also find us at World reference in Small Domestic Equipment and professional coffee machines, Groupe SEB operates with a unique portfolio of 40 top brands (including Tefal, Seb, Rowenta, Moulinex, Krups, Lagostina, All-Clad, WMF, Emsa, Supor), marketed through multi-format retailing. Selling more than 400 million products a year, it deploys a long-term strategy focused on innovation, international development, competitiveness, and client service. Present in over 150 countries, Groupe SEB generated sales of €8.3bn in 2024 and has more than 32,000 employees worldwide. SEB S.A. ■ 1 The dividend will be raised to 3.08 euros per share for shares benefiting from the loyalty bonus.
